Clinical trials: Psoriasis, completed
Psoriasis
Chinese Medicine for Patients With Psoriasis
Psoriasis is an inflammatory skin disease with huge negative impact on the quality of life of the patients, and has an overall prevalence of 2% to 3% in the general population.
- Trial name
- NCT05295979
- Testing
- Inflammatory skin disease formula
- Where
- Hong Kong
- Volunteers
- 60 people
- Sponsor
- Chinese University of Hong Kong
Plaque Psoriasis
The Efficacy and Safety of TLL018 in Moderate-to-severe Plaque Psoriasis
This is a Phase 2, multicenter, randomized, double-blinded, parallel dose group, placebo-controlled, dose-ranging study to evaluate the efficacy and safety of 2 doses of TLL018 as therapy in approximately 90 participants with…
- Trial name
- NCT05772520
- Testing
- TLL018 tablets
- Where
- 35 sites in United States
- Volunteers
- 82 people
- Sponsor
- Hangzhou Highlightll Pharmaceutical Co., Ltd
Psoriasis, Quality of Life
Psoriasis and Its Impact on Quality of Life Among Psoriatic Patients
This work aimed to study some epidemiological features and the clinical profile of patients having psoriasis visiting the Dermatology and Venereology departments of Tanta University Hospitals and to assess the impact of disease…
- Trial name
- NCT07709169
- Testing
- Quality of Life assessment
- Where
- Egypt
- Volunteers
- 170 people
- Sponsor
- Tanta University
Plaque Psoriasis
Efficacy and Safety of Roflumilast Cream 0.3% in Subjects With Plaque Psoriasis: a Phase 3 Study
This study is a multi-center, randomized, double-blind, vehicle-controlled phase III study to evaluate the efficacy, safety, and PK profile of roflumilast cream 0.3% in Chinese subjects ≥6 years of age with plaque psoriasis.
- Trial name
- NCT06648772
- Testing
- Roflumilast Cream 0.3%, Vehicle cream
- Where
- 31 sites in China
- Volunteers
- 190 people
- Sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Chinese Adult Study Participants With Moderate to Severe Plaque Psoriasis
The primary purpose of this study is to compare the efficacy of bimekizumab administered subcutaneously (sc) for 16 weeks versus placebo in the treatment of study participants with moderate to severe plaque psoriasis (PSO).
- Trial name
- BE SHINING (NCT06011733)
- Testing
- Bimekizumab
- Where
- 18 sites in China
- Volunteers
- 133 people
- Sponsor
- UCB Biopharma SRL
Chronic Plaque Psoriasis
Skin Transcriptional Profiles In Psoriatic Patients Under Adalimumab Biotherapy
The expertise in the characterization of transcriptomics profile in lesional psoriatic skin and on the availability of innovative therapy for these patients.The investigators propose to follow the modification of the skin…
- Trial name
- CYTOPSO (NCT01872546)
- Testing
- Adalimumab Every Week
- Where
- France
- Volunteers
- 18 people
- Sponsor
- Poitiers University Hospital
Plaque Psoriasis, Scalp Psoriasis
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/or Scalp Psoriasis
The purpose of this study is to evaluate the efficacy of guselkumab treatment versus placebo in skin of color participants with predominant moderate-to-severe body psoriasis or predominant moderate-to-severe scalp psoriasis by…
- Trial name
- VISIBLE (NCT05272150)
- Testing
- Guselkumab
- Where
- 94 sites in United States, Canada
- Volunteers
- 211 people
- Sponsor
- Janssen Research & Development, LLC
Psoriasis Guttate, Plaque Psoriasis
Guselkumab Immunogenetics
This is a two-arm open-label study to evaluate the clinical and immunogenetic responses of patients with plaque or guttate psoriasis to treatment with guselkumab.
- Trial name
- TIG (NCT04645355)
- Testing
- Guselkumab
- Where
- United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Psoriasis, Obesity
Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight
The main purpose of this study is to demonstrate that when participants with moderate to severe plaque psoriasis and obesity or overweight in the presence of at least 1 weight-related comorbid condition receive ixekizumab and…
- Trial name
- TOGETHER-PsO (NCT06588283)
- Testing
- Ixekizumab, Tirzepatide
- Where
- 72 sites in United States, Puerto Rico
- Volunteers
- 281 people
- Sponsor
- Eli Lilly and Company
Psoriasis
Effectiveness of a Digital Health Application for Psoriasis
This clinical trial with 348 patients with psoriasis aims to investigate the effectiveness of a self-guided online program for patients with psoriasis.
- Trial name
- NCT06027034
- Testing
- Online program for psoriasis (GAIA-PSO-01)
- Where
- Germany
- Volunteers
- 348 people
- Sponsor
- Gaia AG
Plaque Psoriasis, Psoriasis
A Study to Assess Efficacy and Tolerability of Topical Skincare Products on Psoriasis Patients
Subjects having mild-to-severe plaque psoriasis, with active target lesion plaques, and currently on or starting a prescription treatment for plaque psoriasis will apply a topical skincare regimen to one side of the body.
- Trial name
- NCT06357221
- Testing
- Cetaphil
- Where
- 3 sites in United States
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Galderma R&D
Psoriasis
A Study to Evaluate the Effect of Deucravacitinib on Quality of Life in Participants With Plaque Psoriasis in a Community Setting
The purpose of this study is to evaluate the effect of deucravacitinib on quality of life (QoL) in participants with plaque psoriasis in a community setting.
- Trial name
- ARTISTYK (NCT05701995)
- Testing
- Deucravacitinib
- Where
- 38 sites in United States, Puerto Rico
- Volunteers
- 180 people
- Sponsor
- Bristol-Myers Squibb
Plaque Psoriasis
A Long-term Extension Study of JNJ-77242113 in Participants With Moderate-to-Severe Plaque Psoriasis
The purpose of this study is to evaluate long-term clinical response of JNJ-77242113 treatment in participants with moderate-to-severe plaque psoriasis.
- Trial name
- FRONTIER 2 (NCT05364554)
- Testing
- JNJ-77242113
- Where
- 60 sites in United States, Canada and 8 more
- Volunteers
- 227 people
- Sponsor
- Janssen Research & Development, LLC
Psoriasis
Risankizumab Long-term Remission Study
Although the newly developed biologics (drugs derived from living cells cultured in a laboratory) are highly effective in controlling psoriasis, all the biologics should be continuously injected to suppress recurrence of the…
- Trial name
- NCT04630652
- Testing
- Risankizumab-Rzaa, Punch biopsies of the skin at baseline visit, Punch biopsies of the skin at week 28 visit
- Where
- 3 sites in United States
- Volunteers
- 24 people
- Sponsor
- Jaehwan Kim
Psoriasis
Maximal Usage Pharmacokinetics and Safety Study of ARQ-154 Foam 0.3% in Pediatric Participants With Scalp and Body Psoriasis
This study will evaluate the systemic exposure and characterize the plasma pharmacokinetic (PK) profile and assess the safety and tolerability of ARQ-154 foam 0.3%.
- Trial name
- NCT07340216
- Testing
- ARQ-154 Foam 0.3%
- Where
- 5 sites in United States
- Volunteers
- 22 people
- Sponsor
- Arcutis Biotherapeutics, Inc.
Psoriasis, Inflammation
A Proof-of-Activity Study With Orticumab in Subjects With Psoriasis and Cardiometabolic Risk Factors
The primary purpose of this proof-of-activity, phase 2 trial is to evaluate the safety and activity of orticumab in subjects with moderate to severe psoriasis and cardiometabolic risk factors.
- Conditions
- Psoriasis, Inflammation, Coronary Artery Disease, Cardiometabolic Syndrome
- Trial name
- NCT04776629
- Testing
- Orticumab
- Where
- 13 sites in United States
- Volunteers
- 77 people
- Sponsor
- Abcentra
Psoriasis
Comparative Study of CMAB015 and Secukinumab for Patients With Moderate to Severe Plaque Psoriasis
The goal of this trial is to assess whether the efficacy of CMAB015 is similar to that of Secukinumab in patients with moderate-severe chronic plaque psoriasis.
- Trial name
- NCT06398652
- Testing
- CMAB015, Secukinumab
- Where
- China
- Volunteers
- 336 people
- Sponsor
- Taizhou Mabtech Pharmaceutical Co.,Ltd
Psoriasis, Alopecia Areata
Improving Disease Severity
Phototherapy, including ultraviolet B (UVB) and ultraviolet A (UVA) light, has been used to treat a number of dermatologic conditions.
- Conditions
- Psoriasis, Alopecia Areata, Polymorphous Light Eruption
- Trial name
- NCT05391178
- Testing
- Lumiton yarn sleeve, Lumiton yarn hat, Lumiton yarn shirt
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Wake Forest University Health Sciences
Plaque Psoriasis
A Study of JNJ-77242113 for the Treatment of Moderate-to-Severe Plaque Psoriasis
The purpose of the study is to evaluate the efficacy of an oral tablet formulation of JNJ-77242113 compared with placebo in participants with moderate-to-severe plaque psoriasis.
- Trial name
- SUMMIT (NCT05357755)
- Testing
- JNJ-77242113
- Where
- 34 sites in United States, Canada and 4 more
- Volunteers
- 90 people
- Sponsor
- Janssen Research & Development, LLC
Psoriasis, Pruritus
Evaluation of the Efficacy and Tolerance of the Medical Device RL3020-DP0364 in Adult Population With Stable Mild Plaque Psoriasis, Dry Skin and Pruritus
The product RL3020-DP0364 developed by Pierre Fabre Laboratories moisturizes durably and repairs dry or atopic skin, especially in the case of certain dermatoses (atopic dermatitis, ichthyosis, etc ...) and erythema induced by…
- Conditions
- Psoriasis, Pruritus, Dry Skin
- Trial name
- NCT06800755
- Testing
- Dexeryl (RL3020-DP0364)
- Where
- Poland
- Volunteers
- 40 people
- Sponsor
- Pierre Fabre Dermo Cosmetique